346 related articles for article (PubMed ID: 18678357)
1. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
2. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
3. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
5. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.
Lewis JS; Sharp TL; Laforest R; Fujibayashi Y; Welch MJ
J Nucl Med; 2001 Apr; 42(4):655-61. PubMed ID: 11337556
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
Bradshaw TJ; Yip S; Jallow N; Forrest LJ; Jeraj R
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):399-405. PubMed ID: 24685446
[TBL] [Abstract][Full Text] [Related]
7. Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.
Clausen MM; Hansen AE; Lundemann M; Hollensen C; Pommer T; Munck Af Rosenschöld P; Kristensen AT; Kjær A; McEvoy FJ; Engelholm SA
Radiat Oncol; 2014 Oct; 9():228. PubMed ID: 25319766
[TBL] [Abstract][Full Text] [Related]
8. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.
Obata A; Yoshimoto M; Kasamatsu S; Naiki H; Takamatsu S; Kashikura K; Furukawa T; Lewis JS; Welch MJ; Saji H; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2003 Jul; 30(5):529-34. PubMed ID: 12831991
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.
Bradshaw TJ; Bowen SR; Jallow N; Forrest LJ; Jeraj R
J Nucl Med; 2013 Nov; 54(11):1931-7. PubMed ID: 24042031
[TBL] [Abstract][Full Text] [Related]
10. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
[TBL] [Abstract][Full Text] [Related]
11. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
12. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
[TBL] [Abstract][Full Text] [Related]
13. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models.
Tanaka T; Furukawa T; Fujieda S; Kasamatsu S; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2006 Aug; 33(6):743-50. PubMed ID: 16934693
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation.
Kersemans V; Cornelissen B; Hueting R; Tredwell M; Hussien K; Allen PD; Falzone N; Hill SA; Dilworth JR; Gouverneur V; Muschel RJ; Smart SC
PLoS One; 2011; 6(11):e25911. PubMed ID: 22102855
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.
Carlin S; Zhang H; Reese M; Ramos NN; Chen Q; Ricketts SA
J Nucl Med; 2014 Mar; 55(3):515-21. PubMed ID: 24491409
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
[TBL] [Abstract][Full Text] [Related]
17. Predicting location of recurrence using FDG, FLT, and Cu-ATSM PET in canine sinonasal tumors treated with radiotherapy.
Bradshaw T; Fu R; Bowen S; Zhu J; Forrest L; Jeraj R
Phys Med Biol; 2015 Jul; 60(13):5211-24. PubMed ID: 26083082
[TBL] [Abstract][Full Text] [Related]
18. (64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry.
Hansen AE; Kristensen AT; Jørgensen JT; McEvoy FJ; Busk M; van der Kogel AJ; Bussink J; Engelholm SA; Kjær A
Radiat Oncol; 2012 Jun; 7():89. PubMed ID: 22704363
[TBL] [Abstract][Full Text] [Related]
19. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.
Nyflot MJ; Harari PM; Yip S; Perlman SB; Jeraj R
Radiother Oncol; 2012 Oct; 105(1):36-40. PubMed ID: 23068711
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.
Clausen MM; Hansen AE; Af Rosenschold PM; Kjaer A; Kristensen AT; McEvoy FJ; Engelholm SA
Radiat Oncol; 2013 Nov; 8():262. PubMed ID: 24199939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
